ENDONOVO THERAPEUTICS, INC.
Income Statement
| Line Item | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|
| Revenue | $4.3K | $24.2K | $22.9K | $30.6K | $45.5K | $51.2K |
| Cost of Revenue | $2.2K | $15.5K | $14.0K | — | — | — |
| Gross Profit | $2.1K | $8.7K | $8.9K | — | — | — |
| Gross Margin | 49.3% | 36.0% | 38.9% | — | — | — |
| Operating Expenses | ||||||
| Research & Development | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — |
| Operating Income | $-2.6M | $-2.2M | $-2.4M | $-1.7M | $-95.5K | $-78.0K |
| Operating Margin | -60,132.7% | -9,057.6% | -10,607.6% | -5,697.5% | -209.7% | -152.3% |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | $-6.8M | $-959.5K | $-2.9M | $-1.9M | $-93.3K | $-68.6K |
| Income Tax Expense | $0 | $0 | $532 | $0 | $800 | $800 |
| Net Income | $-6.8M | $-959.5K | $-2.9M | $-1.9M | $-94.1K | $-69.4K |
| Net Margin | -158,633.9% | -3,966.2% | -12,634.5% | -6,260.6% | -206.6% | -135.5% |
| EPS (Basic) | $-0.04 | $-0.02 | $-1.98 | $-0.02 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.04 | $-0.02 | $-1.98 | $-0.02 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 209.6M | 162.9M | 1.7M | 96.3M | 99.8M | 99.8M |
| Shares Outstanding (Diluted) | 209.6M | 162.9M | 1.7M | 96.3M | 99.8M | 99.8M |
| Dividends Per Share | — | — | — | — | — | — |